Rare Sugar Members Stimulate Glucagon-Like Peptide-1 Release and Suppress Food Intake in Mice

If you formulate reduced-sugar foods, D-allulose just became more interesting. A mouse study (DOI: 10.3390/nu17071221) tested whether rare sugars can trigger the gut hormone GLP-1. The results point to a clear mechanism for satiety and glucose control.

Why this matters

Rare sugars occur naturally in tiny amounts. They taste sweet but deliver few calories. That makes them attractive as functional ingredients. The catch: we need evidence that they do more than replace sugar. This paper supplies that evidence for D-allulose.

What the study did

The team gave mice single oral doses of D-allulose. They measured active GLP-1 in portal vein plasma. Then they tracked short-term food intake. To prove GLP-1 drove the effect, they blocked the GLP-1 receptor with exendin(9-39).

Key findings

The data are straightforward. A single gavage of 1 g/kg or 3 g/kg D-allulose significantly raised active GLP-1 concentrations in the portal vein. Food intake dropped in a dose-dependent manner. When the GLP-1 receptor was blocked, that suppression disappeared. That is strong evidence that D-allulose acts through GLP-1 signaling, not through some unrelated metabolic side effect.

Dose of D-allulose	Observed effect
1 g/kg single oral gavage	Significantly increased portal active GLP-1
3 g/kg single oral gavage	Significantly increased portal active GLP-1
Both doses	Short-term food intake suppressed in a dose-dependent way
With GLP-1 receptor antagonist exendin(9-39)	Food intake suppression blocked

The dose-response relationship matters. Formulators want ingredients with predictable effects. Here, more D-allulose meant more suppression. That gives you a lever to work with when designing products for appetite control.

What this means for manufacturers

You can start thinking about D-allulose as more than a bulk sweetener. It may help with portion control and post-meal glucose management by stimulating GLP-1 release. That positions it well for products aimed at weight management, diabetes-friendly formulations, and satiety-focused snacks.

But keep the limitations in view. This is a mouse study. The doses are high relative to typical human consumption. You will need human data before making claims. Still, the mechanistic evidence is clean. Blocking the GLP-1 receptor wiped out the food intake effect. That is exactly what you want to see in a preclinical study.

For ingredient buyers, the practical question is supply and stability. D-allulose is commercially available, but its functional benefits depend on formulation. Heat, pH, and matrix interactions can affect how much reaches the gut and how quickly. Work with suppliers who can provide stability data in your application.

FAQ

Does D-allulose work through the same pathway as prescription GLP-1 drugs?
No. Drugs like GLP-1 receptor agonists activate the receptor directly. D-allulose appears to stimulate the body’s own release of active GLP-1. The receptor is the same, but the input is different.

Are all rare sugars equally effective?
The key evidence here focuses on D-allulose. Other rare sugars may act differently. Treat each sugar as its own ingredient until you see comparative data.

What dose did the mice receive?
They received 1 g/kg and 3 g/kg by single oral gavage. Both doses significantly increased portal active GLP-1, and food intake suppression was dose-dependent.

The next step is human research. If those trials confirm what mice show, D-allulose could become a dual-purpose ingredient: a sweetener that also helps regulate appetite. That is a compelling value proposition for formulators looking beyond sugar reduction.